Pierre‐Yves Dumas
YOU?
Author Swipe
View article: Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
TP53 mutations characteristics among t-MN PARPi national cohort.
View article: Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Commutation plot visualizing the mutated genes in t-MN after OC according to PARPi treatment.
View article: Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Waffle chart (%) of patients addressed for cytopenia exploration after OC exposed to a PARPi treatment from cytopenia diagnosis (A) and cytopenia diagnosis based on NGS results (B). Dot plots (C) showing the median WBC, hemoglobin, and pla…
View article: Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Flow chart of the study displaying the three cohorts.
View article: Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Patient characteristics of the national cohort according to the type of PARPi received (olaparib vs. other PARP inhibitors).
View article: Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Univariate analysis for overall survival from t-MN diagnosis of patients diagnosed with t-MN after OC according to PARPi exposure.
View article: Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study.
Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study. Open
IntroductionResults from pivotal clinical trials evaluating the combination of intensive chemotherapy (IC) with inhibitors of IDH1, IDH2, menin, FLT3 and BCL2 are expected in the coming years. These results could transform the therapeutic …
View article: Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline
Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline Open
Introduction: Midostaurin (MIDO) was approved by the FDA in 04/2017 for the treatment of FLT3 mutated AML patients in combination with intensive chemotherapy (ICT) with daunorubicin (DAUNO) administered at 60 mg/m² for 3 days based on the …
View article: Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis
Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis Open
Introduction In patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy, the combination of ivosidenib and azacitidine (IVO+AZA) is approved in the USA and Europe for patients with isocitrate dehydrogenase 1 (ID…
View article: Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients Open
In the European LeukemiaNet (ELN) 2022 recommendations, myelodysplasia-related (MR) gene mutations were classified as a novel adverse prognostic category for intensively treated acute myeloid leukemia (AML). To assess the prognostic impact…
View article: Intensive Chemotherapy with or without Midostaurin in Adults ≥60 years old with FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study
Intensive Chemotherapy with or without Midostaurin in Adults ≥60 years old with FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study Open
The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3-mutated acute myeloid leukemia (AML); however, real-world data in elderly patients (≥ 60 years) are limited. This large, retros…
View article: Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders Open
Supplementary Figures
View article: Data from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
Data from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders Open
Purpose:PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to…
View article: Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders Open
Supplementary Tables
View article: Bifocal Nocardiosis Mimicking Neutrophilic Dermatosis in an Immunocompromised Patient
Bifocal Nocardiosis Mimicking Neutrophilic Dermatosis in an Immunocompromised Patient Open
View article: Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An <scp>IPC</scp>‐<scp>DATAML</scp>‐<scp>MSKCC</scp> Retrospective Study
Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An <span>IPC</span>‐<span>DATAML</span>‐<span>MSKCC</span> Retrospective Study Open
View article: Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study
Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study Open
Objectives Antibiotic prophylaxis for patients with cancer remains a controversial issue and is not broadly recommended for hematological malignancies. The venetoclax (VEN) and azacitidine (AZA) combination allows for high rates of complet…
View article: Low Dimensional Representation of Multi‐Patient Flow Cytometry Datasets Using Optimal Transport for Measurable Residual Disease Detection in Leukemia
Low Dimensional Representation of Multi‐Patient Flow Cytometry Datasets Using Optimal Transport for Measurable Residual Disease Detection in Leukemia Open
Representing and quantifying Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow, is essential in the prognosis and follow‐up of AML patients. As traditional cytologica…
View article: Relapsed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia responds well to a combination of modified hyper‐CVAD, blinatumomab and tyrosine kinase inhibitor
Relapsed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia responds well to a combination of modified hyper‐CVAD, blinatumomab and tyrosine kinase inhibitor Open
Introduction Adults with relapsed or refractory Philadelphia chromosome‐positive B‐cell precursor acute lymphoblastic leukaemia (R/R Ph+ BCP‐ALL) have a dismal outcome. Blinatumomab as a single agent has shown activity in R/R Ph‐ BCP‐ALL, …
View article: Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm
Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm Open
International audience
View article: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies Open
Not available.
View article: Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries
Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries Open
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate‐dose cytarabine (IDAC). However, no study has demonstrated the superiorit…
View article: Midostaurin shapes macroclonal and microclonal evolution of <i>FLT3</i>-mutated acute myeloid leukemia
Midostaurin shapes macroclonal and microclonal evolution of <i>FLT3</i>-mutated acute myeloid leukemia Open
Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), complete remission rates are close to 60% to 70%, and relapses occur…
View article: Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study Open
View article: Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment Open
Venetoclax‐azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE‐A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tol…
View article: Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries. Open
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiorit…
View article: Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study Open
Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/ BCR::ABL1 , a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification. However, there is little …
View article: Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study. Open
Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/BCR::ABL1, a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification. However, there is little da…
View article: Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy
Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy Open
Background Acute myeloid leukemia (AML) with myelodysplasia‐related characteristics is a heterogeneous subset of AML that has been challenged throughout the history of myeloid malignancies classifications, considered to have similar outcom…
View article: AML-477 Real-World Treatment Patterns and Patient Characteristics Among Patients With Acute Myeloid Leukemia (AML) in the USA, UK, and France
AML-477 Real-World Treatment Patterns and Patient Characteristics Among Patients With Acute Myeloid Leukemia (AML) in the USA, UK, and France Open